Johnson & Johnson and Janssen won a four-patent case against Sandoz over Spravato, potentially delaying generic esketamine treatment until 2035.

The patents cover esketamine-based depression treatments, including dosing methods and a specific formulation. The case illustrates how companies may seek protection for established psychedelic-like compounds through new formulations, regimens or delivery methods, as development expands across psilocybin, ketamine and MDMA.